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Abstract: Criminal-legal involved women experience significant barriers to preventive cervical care,
and consequently there is a higher incidence of cervical cancer in this population. The purpose
of this study is to identify variables that may facilitate abnormal Pap follow-up among criminal-
legal involved women living in community settings. The study included n = 510 women with
criminal-legal histories, from three U.S. cities—Birmingham, AL; Kansas City, KS/MO; Oakland, CA.
Participants completed a 288-item survey, with questions related to demographics, social advantages,
provider communication, and reasons for missing follow-up care. There were n = 58 women who
reported abnormal Pap testing, and n = 40 (69%) received follow-up care. Most women received
either repeat Pap/HPV testing (n = 15, 38%), or colposcopy and/or biopsy (n = 14, 35%). Women who
did not follow-up (n = 15, 26%) cited that they forgot (n = 8, 53%), were uninsured (n = 3, 20%),
or were reincarcerated (n = 3, 20%). In a multivariate analysis, both having a primary care provider
(OR 4.6, 95% CI 1.3–16.0) and receiving specific provider communication about follow-up
(OR 3.8, 95% CI 1.1–13.2) were independent predictors for abnormal Pap follow-up. Interventions
that offer linkages to providers in the community or ensure abnormal Pap care plans are commu-
nicated effectively may mitigate the disparate incidence of cervical cancer among criminal-legal
involved women.
Keywords: cervical cancer disparities; criminal-legal involved women; abnormal Pap follow-up
1. Introduction
Cervical cancer is preventable with routine Papanicolaou (Pap) testing and dysplasia
treatment, yet women with criminal-legal histories are five times more likely to develop
cervical cancer in their lifetimes [1,2]. There are nearly two million U.S. women with a his-
tory of criminal-legal involvement, which includes women who are housed in correctional
facilities, supervised under probation, parole, or other community-based monitoring sys-
tems, or women who are previously incarcerated without ongoing oversight [3]. Surveys of
incarcerated women in the U.S. report that 67–84% of criminal-legal involved women have
completed Pap testing within three years, which is comparable to the Pap testing rates
cited for all women [4–6]. However, after receiving an abnormal Pap result, only 21–66% of
criminal-legal involved women obtain the recommended follow-up—which is much lower
than the 90% follow-up rate observed among women in the general population [7–10].
While criminal-legal involved women may have access to Pap testing, they have higher
rates of cervical dysplasia, and are less likely to receive the necessary surveillance and
treatments that can prevent the progression to cervical cancer.
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There have been efforts to expand preventive cervical care within jail and prison
settings, but this approach has limitations. In the U.S., follow-up after an abnormal
Pap diagnosis from cytology testing typically involves receiving human papillomavirus
(HPV) typing and/or colposcopy, with or without a cervical biopsy. In the cases of high-
grade dysplasia, providers may advise women to have additional preventive treatments,
including ablation procedures, loop electrical excision procedure (LEEP), or hysterectomy.
Screening with primary HPV testing is now recommended in the U.S., but this has not yet
been widely adopted as standard practice [11]. Most jails and prisons are not equipped to
provide even basic gynecologic care, much less offer testing and procedures that require
access to specialized diagnostic equipment [12]. Furthermore, most women are released
within a short period of time and do not have the opportunity to participate in jail-based
cervical health programs [9,13].
Following release from jail or prison, criminal-legal involved women encounter sig-
nificant barriers to cervical care—they must obtain health insurance and find a primary
care provider, while also securing income, housing, food, and other basic needs [8,14,15].
Barriers that limit access to preventive cervical care have been well studied, but there are
less data on factors that will facilitate abnormal Pap follow-up. In studies of incarcerated
women, abnormal Pap follow-up has been associated with lesion severity, duration of
incarceration, and demographic characteristics [9,10,16]. In those studies, women who
were incarcerated for a longer period after the abnormal Pap result were more likely to com-
ply with the follow-up, as were women with fewer aliases, lower educational attainment,
and a diagnosis of low-grade squamous intraepithelial lesion (LSIL), or higher [9,10,16].
For women without criminal-legal histories, both access to a primary care provider and
aggressive follow-up with tailored provider communication, case management, and univer-
sal colposcopy predicted adherence to abnormal Pap follow-up recommendations [17–19].
Given that 80% of criminal-legal involved women live outside of carceral settings, it is
important to understand what variables enable women to obtain follow-up care for ab-
normal Pap results in their communities [20]. The purpose of this study was to identify
predictors for abnormal Pap follow-up among community-based criminal-legal involved
women from three U.S. cities—Birmingham, AL; Kansas City, KS/MO; and Oakland, CA.
2. Materials and Methods
This is a cross-sectional study of criminal-legal involved women with abnormal Pap
testing from three U.S. cities. Data were obtained from a baseline survey administered
from March 2019 to June 2020 for the tri-city cervical cancer prevention study, which is
an ongoing longitudinal (2019–2024) study with criminal-legal involved women who are
living in community settings. All participants were women age 18 or older and recruited
from cohorts of women in ongoing, separate studies at each location. The three cohorts
were merged to provide the investigative team with access to existing groups of hard-to-
reach women and follow a robust, multi-site cohort. All women were living outside of
the jail/prison setting; Oakland women were on probation and Kansas City women were
all recently released from city/county jails without any ongoing oversight. Birmingham
women were receiving ongoing monitoring through an outpatient case management facility,
which included supervision under diversion programs such as drug court, mental health
court, probation, and life after prison/parole. The women at each study location were under
varying degrees of legal-based oversight, but they were all released to live in community
settings by their prior correctional facility.
Participants were given a 288-item survey that investigated preventive cervical care
and other health behaviors. The survey included open-ended and multiple-choice ques-
tions informed by the National Cancer Institute Health Information National Trends Survey
(NCI HINTS), cervical cancer section [21]. Information on Pap testing and follow-up care
were designed using the American College of Obstetrics and Gynecologists (ACOG), Amer-
ican Society for Colposcopy and Cervical Pathology (ASCCP), and the U.S. Preventive
Service Task Force (USPSTF) guidelines on cervical cancer screening and follow-up [22–24].
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At the time of survey development, the recommended strategies for cervical cancer screen-
ing included the following: (1) cervical cytology alone every three years for women aged
21–29, (2) cervical cytology alone every three years for women aged 30–65, or (3) cervical
cytology and HPV co-testing every five years for women aged 30–65 [22–24]. In 2018,
the USPSTF updated their guidelines to include primary HPV testing every five years as
the optimal screening approach for women aged 30–65, which has been recommended by
many international cervical cancer screening organizations including the World Health
Organization [23,25]. As of 2021, ACOG has also recommended HPV screening alone as
the preferred method for cervical cancer screening [11]. However, at the time of survey
administration, this approach was not yet widely adopted by U.S. practitioners so the
survey did not include HPV testing alone as a possible response for type of cervical cancer
screening. For abnormal Pap follow-up care, ACOG, USPSTF, and ASCCP recommend
that women with low-grade Pap results have either HPV co-testing, a repeat Pap in one
year, or immediate colposcopy depending on their age and HPV result (when available).
Women with suspected high-grade lesions are advised to have HPV testing (if not already
obtained) and either colposcopy with biopsy, or excision with a loop electrosurgical excision
(LEEP) procedure depending on age and HPV status. Women with high-grade lesions may
also elect to proceed with a hysterectomy if they do not desire future childbearing [22–24].
To assess participant’s cervical cancer screening status, women were asked multiple-
choice questions about the timing of their last Pap test and whether they had an HPV co-test.
Data on Pap timing were then stratified by time intervals of less than three years, three to
five years, or more than five years, given that the USPSTF/ACOG/ASCCP guidelines
consider a woman to be up-to-date on Pap testing within these intervals depending on
age and the screening strategy that was utilized [22–24]. Participant’s Pap results were
assessed with a multiple-choice question, “The last time you had a Pap test, did you get
an “abnormal” result? In other words, did they say that they needed you to follow up for
more testing?” and an open-ended question, “What were the results of your last Pap test?”
Those participants who self-reported abnormal results were then asked about follow-up
care. Women were given a multiple-choice question, “Did you get the recommended
follow-up after your Pap test?” and then stratified according to whether they responded
“yes” or “no.” Women with follow-up were asked additional questions about the type of
follow-up care they received, and participants without follow-up were asked about reasons
why they were unable to obtain recommended care [21,26–30].
To identify predictors for abnormal Pap follow-up, the survey assessed additional
demographic information and variables that were found to have significance in previous
studies of abnormal Pap follow-up in women with and without criminal-legal histories,
including demographic information, duration of incarceration, access to a primary care
provider, and provider communication [9,10,16–19]. All items were multiple choice or open-
ended except for a question about efficacy of provider communication, which was scaled.
In that question, participants were asked “My provider effectively explains information”
according to the following four-item scale: all of the time, most of the time, some of the time,
or never; for this item, a lower score indicates that providers were more likely to effectively
explain information. Lesion severity, which has been associated with abnormal Pap follow-
up in other studies, could not be assessed as we did not have access to medical records
nor did the participants self-report their impression of whether or not their abnormal Pap
tests were low or high grade [9]. All questions were adapted from validated surveys and
designed to consider the unique needs of women with criminal-legal histories [21,26–30].
For data analysis, women in the cohort who reported abnormal results after their most
recent Pap test were identified. Data on cervical cancer prevention behaviors, including
Pap testing and follow-up, were stratified according to study site and compared using
Chi-square for categorical variables and t-test for continuous variables. A p-value <0.05
was considered significant for bivariate comparisons. Descriptive statistics were used to
describe types of follow-up care that women utilized or reasons why women did not obtain
follow-up. Participants were then grouped according to whether they did or did not obtain
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abnormal Pap follow-up care. Independent variables included for comparison were demo-
graphic characteristics, social advantages (age, years incarcerated, education, employment,
housing, health insurance, and healthcare provider), and perceptions of provider commu-
nication. We compared study groups with and without follow-up care using Chi-square
for categorical variables and t-test for continuous variables with a p-value < 0.05 indicating
statistical significance. After controlling for age, a multivariate analysis was performed
to identify factors independently associated with obtaining follow-up care. Odds ratios
(ORs) with Wald 95% confidence intervals (CIs) and corresponding p-values were reported.
Statistical analysis was performed using SAS software, version 9.3 (SAS Institute Inc., Cary,
NC, USA).
3. Results
3.1. Description of the Entire Cohort
There were n = 510 criminal-legal involved women in the cohort, which included
n = 164 Birmingham, n = 108 Kansas City, and n = 238 Oakland women. The key demo-
graphic differences among the women in the three sites were age, race, and insurance
status. The Kansas City women were younger (42.4 ± 11.7) compared to the other sites
(Birmingham, 40.6 ± 11.3; Oakland, 45.4 ± 12.2; p < 0.001). The Oakland cohort was
comprised of mostly black women (black, 80.7%; white, 4.6%), whereas the largest portions
of women in Birmingham (black, 38.4%; white, 53.0%) and Kansas City (black, 34.3%; white,
43.5%) were white (p < 0.001). More criminal-legal women in Oakland had health insurance
(94.5%) compared to women in Birmingham (39.0%) and Kansas City (51.9%, p < 0.001).
There were no differences in educational attainment, employment/sources of money, sex-
ual orientation, housing stability, living situation, cumulative time spent in jail/prison,
history of violence, diagnosis of mental illness, or substance use across the study sites.
In the cohort, there were n = 416 (82%) women with normal Pap results and n = 36 (7%)
women who did not recall their Pap result. Additional demographic information by study
site and data on women with normal Pap testing will be reported elsewhere.
3.2. Description of Women with Abnormal Pap Testing
Within the cohort, there were n = 58 (11.4%) criminal-legal involved women who reported
that their last Pap test was abnormal. The mean age of these women was 41.2 ± 9.9, and they
consisted of 38% (n = 22) black, 52% (n = 30) white, 7% (n = 4) Hispanic, and 4% (n = 2)
other women. More of the women with abnormal Pap results were from Kansas City (31%)
and Birmingham (41%) than Oakland (28%, p = 0.003). Otherwise, there were no significant
differences across the study sites, including receipt of abnormal Pap follow-up care.
Among the women with abnormal Pap testing, the majority (62%) reported that their
last Pap test was within 3 years. However, 24% reported a Pap test more than 5 years
ago, suggesting that a large proportion of this group was not up-to-date on preventive
cervical care. Most women had their Pap test as part of a routine well-woman exam (48%)
and 12% reported a history of a prior abnormal Pap test results. Most women relied on a
community clinic or health department (40%) for cervical cancer screening, but 17% relied
on jail/prison-based screening programs (Table 1).
Overall, 69% (n = 40) of criminal-legal involved women with abnormal Pap results
obtained follow-up. Of those women, the majority received either repeat Pap/HPV co-
testing (n = 15, 38%), or a colposcopy and/or biopsy (n = 14, 35%). Only n = 3 (8%) received
a LEEP/ablative procedure or hysterectomy, respectively. There were n = 15 (26%) women
who did not complete the follow-up, and the most commonly cited reasons were that
they forgot (n = 5, 33%), lacked health insurance (n = 3, 20%), or were reincarcerated
(n = 3, 20%; Table 2). The types of follow-up care and reasons for no follow-up care were
compared across the study sites, but there were no significant differences (data not shown).
There were also n = 3 (5%) with abnormal Pap results who did not provide any further
details on their follow-up, and n = 3 (20%) whose appointment had not yet occurred.
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Table 1. Criminal-legal system involved women who reported abnormal results at time of last Pap
test according to study site.






n = 16 p-Value
Abnormal Pap (n = 58) 58 (100%) 18 (31.0) 24 (41.4) 16 (27.6) 0.0032
Timing of last Pap test 0.9032
<3 years ago 36 (62.0) 9 (50.0) 16 (66.7) 11 (68.8)
3–5 years ago 5 (8.6) 1 (5.6) 2 (8.3) 2 (12.5)
>5 years ago 14 (24.1) 5 (27.8) 6 (25.0) 3 (18.8)
Unknown/prefer not to answer 3 (5.2) 3 (16.7) 0 (0) 0 (0)
Reason for Pap test 0.1283
Well-woman or routine care 28 (48.3) 9 (50.0) 9 (37.5) 10 (62.5)
Having problem/symptom 13 (22.4) 7 (38.9) 5 (20.8) 1 (6.3)
Last Pap abnormal 7 (12.1) 1 (5.6) 3 (12.5) 3 (18.8)
Screening at jail/prison 10 (17.2) 1 (5.6) 7 (29.2) 2 (12.5)
Pap location 0.0559
Doctor’s office/clinic 18 (31.0) 9 (50.0) 8 (33.3) 1 (6.3)
Community clinic/health dept 23 (39.7) 5 (27.8) 9 (37.5) 9 (56.3)
Jail/prison 10 (17.2) 1 (5.6) 5 (20.8) 4 (25.0)
Unknown/prefer not to answer 7 (12.0) 3 (16.7) 2 (8.3) 2 (12.5)
Received follow-up 40 (69.0) 12 (66.7) 14 (58.3) 14 (87.5) 0.1437
Table 2. Abnormal Pap follow-up among criminal-legal involved women.
Variable Total
Types of care among women who completed
follow-up 1 (n = 40)
Repeat Pap or HPV co-test 15 (37.5)
Colposcopy and/or biopsy 14 (35.0)
LEEP or ablative procedure 3 (7.5)
Hysterectomy 3 (7.5)
Unknown/prefer not to answer 5 (12.5)
Reasons for no care among women who did
not follow up 1 (n = 15)
Forgot 5 (33.3)
No transportation 1 (6.7)
No health insurance 3 (20.0)
Could not afford it 2 (13.3)
Reincarceration 3 (20.0)
My drug/alcohol abuse got in the way 1 (6.7)
Has not yet occurred 3 (20.0)
1 Participants were able to select multiple responses to this question.
3.3. Predictors for Abnormal Pap Follow-Up Care
To identify predictors of follow-up care among criminal-legal involved women with
abnormal Pap results, we compared the women who did and did not obtain follow-up
(Table 3). Social advantages associated with abnormal Pap follow-up included older age
(follow-up, 42.8 ± 10.6 years; no follow-up, 37.7 ± 7.1 years; p = 0.04) and having a
primary care provider (follow-up, 67%; no follow-up, 33%; p = 0.005). Women who did not
obtain follow-up were more likely to report full-time employment (15%, follow-up; 47%,
no follow-up; p = 0.049). There were no significant associations between abnormal Pap
follow-up and lifetime years incarcerated, education, housing, or health insurance status.
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Table 3. Variables associated with abnormal Pap follow-up among criminal-legal involved women.
Variable Follow-Upn = 40 (%)
No Follow-Up
n = 15 (%) p-Value
Social advantages
Mean Age 42.8 ± 10.6 37.7 ± 7.1 0.0358
Lifetime years incarcerated, mean (SD) 3.0 ± 3.8 4.6 ± 5.9 0.2993
More than high school education 9 (22.5) 7 (46.6) 0.1511
Full-time work 6 (15.0) 7 (46.6) 0.0493
Stable housing 27 (67.5) 15 (100.0) 0.3961
Health insurance 21 (52.5) 6 (40.0) 0.1494
Primary care provider 27 (67.5) 5 (33.3) 0.0049
Provider communication
Efficacy of provider communication 1 1.4 ± 1.1 1.8 ± 0.3 0.1830
Participant’s recollection of provider
communication following abnormal Pap
result 2
I was told nothing 1 (2.5) 2 (13.3) 0.2248
I was given specific information about
HPV, cell changes, or cancer 18 (45.0) 6 (40.0) 0.4039
I was given specific information about
the follow-up plan 23 (57.5) 5 (33.3) 0.0361
I was told I need a repeat Pap 11 (27.5) 2 (13.3) 0.1661
I was told I need a colposcopy/biopsy 17 (42.5) 3 (20.0) 0.0555
I don’t know/remember 3 (7.5) 3 (20.0) 0.3619
1 Lower score indicates more effective provider communication, 2 participants were able to select multiple
responses to this question.
Provider communication may also influence follow-up after an abnormal Pap result.
Women who obtained follow-up were more likely to recall that they received information
about the next steps in care (follow-up, 58%; no follow-up, 33%; p = 0.04). However, when
comparing women with/without follow-up, according to the specific care plan they re-
ceived (Pap testing or colposcopy/biopsy), there were no significant differences. Receiving
specific information about HPV status or dysplasia also did not impact follow-up status.
There was no difference in follow-up among those women who did not know or remember
what they were told by their provider (follow-up, 8%; no follow-up, 20%; p = 0.36). In a
multivariate analysis, both having a primary care provider (OR 4.6, 95% CI 1.3–16.0) and
receiving specific communication about follow-up care (OR 3.8, 95% CI 1.1–13.2) were
independently associated with abnormal Pap follow-up (Table 4).
Table 4. Independent predictors for abnormal Pap follow-up 1.
Independent Variables Odds Ratio (95% CI) p-Value
Full-time work 0.34 (0.09, 1.28) 0.1112
Primary care provider 4.57 (1.30, 16.01) 0.0177
Specific information about follow-up care 3.78 (1.08, 13.21) 0.0381
1 Controlled for age.
4. Discussion
Criminal-legal involved women are less likely to obtain preventive cervical care, and
the current study provides insight into patient characteristics and provider practices that
may facilitate follow-up among community-based women with abnormal Pap results.
Overall, 69% of the women in the cohort obtained follow-up after an abnormal Pap result,
which is similar to other reports of criminal-legal involved women, but much lower than
the 90% follow-up rate observed in the general U.S. population [7–10]. Those criminal-
legal involved women with older age and a primary care provider were more likely to
obtain follow-up. We also found that specific communication from providers about next
steps in care facilitated follow-up. Leveraging these variables—age, access to a provider,
and provider communication—may offer an opportunity to mitigate the disparate incidence
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of cervical cancer among women with a history of criminal-legal involvement. Although,
it is important to consider that criminal-legal involved women have complex lives and
experience innumerable barriers to healthcare. Ensuring follow-up is likely dependent on
each individual woman’s circumstances and needs.
Having a community-based primary care provider was an independent predictor for
abnormal Pap follow-up among criminal-legal involved women. Most jails and prisons do
not coordinate health care once women are released, so providers and health systems must
facilitate entry into community health care [31]. Many states with Medicaid expansion pro-
grams have developed strategies to enhance health care delivery to formerly incarcerated
persons. These strategies include data exchange, so that a plan or provider is notified when
someone is leaving jail or prison and re-entering the community; jail or prison “in-reach”,
where a clinician meets with an inmate in person or via video conferencing to establish a
relationship and develop a post-release care plan; use of a peer support specialist, who helps
former inmates navigate health care and social service resources; and providing specialized
training to primary care providers to help them better serve the unique needs of individuals
with criminal-legal involvement [32]. These programs are certainly promising, but they
are also state-dependent and only available in the 39 states that have adopted Medicaid
expansion [32,33]. Furthermore, such programs may not necessarily emphasize cervical
care. There is a need for more consistent linkages between criminal-legal involved women
and community providers nationwide, as well as a need to promote cervical health in care
delivery programs.
Another key finding from the current study was the importance of specific provider
communication regarding the follow-up plan. Those women who recalled information
regarding the next steps in care were more likely to obtain follow-up, irrespective of what
providers told them about their actual results or whether they needed a repeat Pap versus
a colposcopy. Pap tests can take several weeks to result after they are collected, so it is
important that providers have a plan for how they will communicate results and the next
steps in care with criminal-legal involved women. Women in this population often have
unstable housing, limited access to landlines, and frequent changes to their cell phone
numbers [14,15]. Therefore, it would be prudent for providers to obtain multiple points
of contact from patients, including contact information for friends or family members
who may be able to reach them. The authors have also found success in maintaining
contact with criminal-legal involved women through social media [34], which could be a
consideration for those clinics that maintain professional social media accounts. Most of the
women, both with and without abnormal Pap follow-up, reported that providers effectively
explained information in their counseling. However, providers should be aware that
criminal-legal involved women have lower health literacy, so it also important to make sure
information is communicated using language that is clear and comprehensible [13,35,36].
There are no data on the relationship between age and cervical cancer prevention
behaviors in criminal-legal involved women. In the general population, studies are conflict-
ing. Some investigators have found no relationship with age, while others have found that
either older or younger women are more likely to be compliant with preventive cervical
care [17–19,37,38]. In a study by Menees et al, authors noted that older women were more
likely to obtain recommended cancer screening, partially because providers were more
likely to encourage cancer screening and follow-up care in older patients, and partially
because the patients themselves perceived that they were at greater risk for a cancer di-
agnosis [37]. These assumptions are problematic because cervical cancer is most often
diagnosed in younger women, aged 35–44 [39]. In our study, the mean age of women
without follow-up was 37, which falls within the age range when cervical cancer is typically
diagnosed. This finding highlights an opportunity to educate both providers and women
with criminal-legal involvement about the age-associated risk for cervical cancer.
Surprisingly, insurance status was not associated with abnormal Pap follow-up in the
current study. Given the expansion of cervical cancer screening and diagnostic services for
low-income and uninsured U.S. women, such as the CDC national breast and cervical cancer
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detection program, it is possible that women who seek follow-up are not necessarily relying
on insurance to obtain care [40,41]. As states with Medicaid expansion are gaining expertise
in enrolling criminal-legal involved persons into insurance plans, it has also become evident
that insurance coverage does not necessarily equate to health care access [32,33]. It is equally
as important to determine how to effectively deliver health care to criminal-legal involved
women, considering the high rates of substance use, mental illness, and numerous social
barriers that affect health behaviors in this population [5,13,42]. Because having a primary
care provider and provider communication may have more influence on abnormal Pap
follow-up than insurance status, interventions at the provider-level are critical to increasing
health equity for criminal-legal involved women.
We expected full-time work to be a social advantage that would facilitate adherence
to abnormal Pap follow-up, but our results suggest that work may be a barrier for criminal-
legal involved women. Those criminal-legal involved women with full-time work have
more reliable income and/or health insurance, but regular work may also limit their
available time to seek preventive cervical care. Data from the U.S. national health interview
study found that full-time workers were less likely to obtain preventive health services,
including cervical cancer screening [43,44]. Health practitioners need innovative strategies
to improve Pap follow-up adherence among criminal-legal involved women with full-
time work. These women are often struggling to maintain housing, childcare, and other
priorities, and may not have time available to seek cervical care during a typical clinic
day [5,15].
Recidivism is another major barrier to preventive health care in the criminal-legal
population [31]. In our study, most women who did not complete follow-up in our cohort
cited that they either forgot or had not yet completed their appointment, but there were
also several women who cited being reincarcerated. Given that over a half of women who
are released from jail or prison are reincarcerated within three years, it is also important
to expand access to cervical care within carceral settings [45]. In a study by Clarke et al.,
having on-site colposcopy significantly decreased the time to completing colposcopy
among women with abnormal Pap testing [9]. While not all jails and prisons can offer more
specialized women’s health services, such as colposcopy, these institutions should ensure
that women with abnormal Pap testing are scheduled for follow-up care in another clinic
or facility that can provide adequate, guideline-concordant cervical care.
The major strength of this study is that it provides data from a multi-site cohort of
women with criminal-legal histories. Because the participants live in cities with different
health resource environments, the results may be more generalizable to criminal-legal
involved women in other U.S. urban settings. An additional strength is that our data
were drawn from women who are living in their community rather than jail or prison,
which is rare in public health research, due to the challenges of maintaining consistent
follow-up with women with criminal-legal involvement [46]. The primary limitation is
that the data were cross sectional, so we do not know whether those women without
follow-up ultimately received care; there were also n = 3 women whose appointment had
not yet occurred, who may have also ultimately completed follow-up. A longitudinal data
set would provide a more comprehensive analysis of health behaviors among criminal-
legal involved women with abnormal Pap testing. Currently, the authors are collecting
longitudinal data on the cohort and will publish the results as they become available.
Another limitation is that we did not collect data from medical records to confirm abnormal
results or assess the severity of dysplasia. Previous studies have found a high degree of
correlation between self-reported Pap data and validated test results among criminal-legal
involved women [47]. Finally, the 288-item survey takes approximately 45 minutes to
complete and can be burdensome for participants.
5. Conclusions
In conclusion, these data suggest that connecting criminal-legal involved women
with providers in their community and ensuring providers offer tailored communication
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after an abnormal Pap test may help women obtain follow-up. Public health programs
that link criminal-legal involved women with community health care, educate providers
about the unique needs of this population, and accommodate women with full-time
work may also facilitate abnormal Pap follow-up. Both providers and patients need
education about the age-associated risk of cervical cancer to ensure that younger women
with criminal-legal histories are receiving appropriate care. Recidivism may also be a
barrier to follow-up, so criminal-legal involved women should receive appropriate social
supports in outpatient settings that will reduce their risk of reincarceration and improve
their connection to consistent healthcare. Criminal-legal involved women are at high risk
for cervical dysplasia and cancer, so it is critical to give these women the assistance they
need to facilitate life-saving preventive cervical care.
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